{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:00:59Z","timestamp":1787785259190,"version":"build-2784847793"},"reference-count":69,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Recent improvements in cancer treatments have significantly improved patient survival rates, which has drawn attention to cardiovascular complications that may arise after using oncological therapies. These complications can seriously affect quality of life and long-term outcomes, sometimes leading to the need for modification or discontinuation of cancer treatment. This highlights the urgent need for effective cardioprotective strategies to prevent and mitigate clinical and subclinical cardiotoxicity, as well as reducing acute and chronic cardiac damage. In this review, we critically evaluate the cardiac biomarkers used in clinical practice for early detection and monitoring of cardiotoxicity, focusing on N-terminal pro-B-type natriuretic peptide and troponins due to their established predictive value. We also explore emerging biomarkers that may improve cardiovascular risk assessment in cancer patients. On the pharmacological front, \u03b2-blockers, angiotensin-converting enzyme inhibitors and sodium\u2013glucose cotransporter 2 inhibitors show potential for mitigating cardiotoxicity, although evidence from randomised trials remains mixed. Non-pharmacological approaches are also discussed, and the aim is to integrate comprehensive cardiovascular prevention into oncology care.<\/jats:p>","DOI":"10.15420\/ecr.2025.26","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:04:13Z","timestamp":1758283453000},"source":"Crossref","is-referenced-by-count":5,"title":["Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches"],"prefix":"10.15420","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9380-861X","authenticated-orcid":false,"given":"Giulia","family":"Tamburrini","sequence":"first","affiliation":[{"name":"Cardiology Department, Policlinico Gemelli, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"de Cobos Garc\u00eda","sequence":"additional","affiliation":[{"name":"Oncology Department, La Paz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-7022","authenticated-orcid":false,"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Cardiology Department, La Paz University Hospital, Madrid, Spain; Hospital La Paz Institute for Health Research, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities. Herz 2020;45:619\u201325. https:\/\/doi.org\/10.1007\/s00059-020-04951-x; PMID:\u00a032514587.","DOI":"10.1007\/s00059-020-04951-x"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Meijers WC, Maglione M, Bakker SJL, et al. Heart failure stimulates tumor growth by circulating factors. Circulation 2018;138:678\u201391. https:\/\/doi.org\/10.1161\/circulationaha.117.030816; PMID:\u00a029459363.","DOI":"10.1161\/CIRCULATIONAHA.117.030816"},{"key":"ref2","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244; PMID:\u00a036017568."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Di Lisi D, Madaudo C, Alagna G, et al. The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail 2022;9:1914\u20139. https:\/\/doi.org\/10.1002\/ehf2.13897; PMID:\u00a035355425.","DOI":"10.1002\/ehf2.13897"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Raisi-Estabragh Z, Murphy AC, Ramalingam S, et al. Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations. JACC CardioOncol 2024;6:631\u201354. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.017; PMID:\u00a039479317.","DOI":"10.1016\/j.jaccao.2024.07.017"},{"key":"ref5","unstructured":"Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in multimodality imaging in\u00a0cardio-oncology: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:1560\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2022.08.743; PMID:\u00a036229093."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mousavi N, Tan TC, Ali M, et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015;16:977\u201384. https:\/\/doi.org\/10.1093\/ehjci\/jev113; PMID:\u00a025925220.","DOI":"10.1093\/ehjci\/jev113"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kang Y, Assuncao BL, Denduluri S, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC CardioOncol 2019;1:208\u201317. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.008; PMID:\u00a032905430.","DOI":"10.1016\/j.jaccao.2019.10.008"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lambert J, Lamacie M, Thampinathan B, et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart 2020;106:817\u201323. https:\/\/doi.org\/10.1136\/heartjnl-2019-316297; PMID:\u00a032098808.","DOI":"10.1136\/heartjnl-2019-316297"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Cardinale D, Mills NL, Mueller C, Study Group on Biomarkers of the ESC Association for Acute CardioVascular Care. Cardiac biomarkers in the field of cardio-oncology. Eur Heart J Acute Cardiovasc Care 2022;11:e1\u20132. https:\/\/doi.org\/10.1093\/ehjacc\/zuac126; PMID:\u00a036215174.","DOI":"10.1093\/ehjacc\/zuac126"},{"key":"ref10","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966\u201383. https:\/\/doi.org\/10.1002\/ejhf.2017; PMID:\u00a033006257."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res 2020;13:431\u201350. https:\/\/doi.org\/10.1007\/s12265-020-10042-3; PMID:\u00a032642841.","DOI":"10.1007\/s12265-020-10042-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517\u201322. https:\/\/doi.org\/10.1016\/s0735-1097(00)00748-8; PMID:\u00a010933366.","DOI":"10.1016\/S0735-1097(00)00748-8"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910\u20136. https:\/\/doi.org\/10.1200\/jco.2009.27.3615; PMID:\u00a020679614.","DOI":"10.1200\/JCO.2009.27.3615"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749\u201354. https:\/\/doi.org\/10.1161\/01.cir.0000130926.51766.cc; PMID:\u00a015148277.","DOI":"10.1161\/01.cir.0000130926.51766.cc"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596\u2013603. https:\/\/DOI.ORG\/10.1161\/CIRCIMAGING.112.973321; PMID:\u00a022744937.","DOI":"10.1161\/circimaging.112.973321"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7:87\u201393. https:\/\/doi.org\/10.1016\/j.ejheart.2004.03.009; PMID:\u00a015642537.","DOI":"10.1016\/j.ejheart.2004.03.009"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zhang N, Wang N, Zhang Y, et al. Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients: a comprehensive analysis using speckle tracking echocardiography. Front Cardiovasc Med 2024;11:1413827. https:\/\/doi.org\/10.3389\/fcvm.2024.1413827; PMID:\u00a039346098.","DOI":"10.3389\/fcvm.2024.1413827"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318\u201326. https:\/\/doi.org\/10.1007\/s00392-007-0633-6; PMID:\u00a018193371.","DOI":"10.1007\/s00392-007-0633-6"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"De Iuliis F, Salerno G, Taglieri L, et al. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. Tumour Biol 2016;37:3379\u201387. https:\/\/doi.org\/10.1007\/s13277-015-4183-7; PMID:\u00a026449821.","DOI":"10.1007\/s13277-015-4183-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405\u201310. https:\/\/doi.org\/10.1373\/clinchem.2005.050153; PMID:\u00a015932966.","DOI":"10.1373\/clinchem.2005.050153"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375\u201380. https:\/\/doi.org\/10.1016\/j.amjcard.2011.01.006; PMID:\u00a021371685.","DOI":"10.1016\/j.amjcard.2011.01.006"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mavinkurve-Groothuis AMC, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging 2013;14:562\u20139. https:\/\/doi.org\/10.1093\/ehjci\/jes217; PMID:\u00a023109647.","DOI":"10.1093\/ehjci\/jes217"},{"key":"ref23","unstructured":"Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:809\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061; PMID:\u00a024291281."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer 2017;24:774\u201382. https:\/\/doi.org\/10.1007\/s12282-017-0778-8; PMID:\u00a028434150.","DOI":"10.1007\/s12282-017-0778-8"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641\u20138. https:\/\/doi.org\/10.1161\/01.cir.96.8.2641; PMID:\u00a09355905.","DOI":"10.1161\/01.CIR.96.8.2641"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218\u201322. https:\/\/doi.org\/10.1007\/s00277-003-0615-3; PMID:\u00a012679885.","DOI":"10.1007\/s00277-003-0615-3"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49:248\u201352. https:\/\/doi.org\/10.1373\/49.2.248; PMID:\u00a012560347.","DOI":"10.1373\/49.2.248"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Pavo N, Raderer M, H\u00fclsmann M, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 2015;101:1874\u201380. https:\/\/doi.org\/10.1136\/heartjnl-2015-307848; PMID:\u00a026416836.","DOI":"10.1136\/heartjnl-2015-307848"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Lenihan DJ, Stevens PL, Massey M, et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail 2016;22:433\u20138. https:\/\/doi.org\/10.1016\/j.cardfail.2016.04.003; PMID:\u00a027079675.","DOI":"10.1016\/j.cardfail.2016.04.003"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy. J Clin Oncol 2017;35:878\u201384. https:\/\/doi.org\/10.1200\/JCO.2015.65.7916; PMID:\u00a028199174.","DOI":"10.1200\/JCO.2015.65.7916"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep 2016;18:51. https:\/\/doi.org\/10.1007\/s11886-016-0731-z; PMID:\u00a027108361.","DOI":"10.1007\/s11886-016-0731-z"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 2019;140:80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497; PMID:\u00a031390169.","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037; PMID:\u00a029567210.","DOI":"10.1016\/S0735-1097(18)31240-3"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Cornell RF, Ky B, Weiss BM, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 2019;37:1946\u201355. https:\/\/doi.org\/10.1200\/JCO.19.00231; PMID:\u00a031188726.","DOI":"10.1200\/JCO.19.00231"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Lunardi M, Al-Habbaa A, Abdelshafy M, et al. Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review. BMC Cancer 2022;22:396. https:\/\/doi.org\/10.1186\/s12885-022-09437-z; PMID:\u00a035413811.","DOI":"10.1186\/s12885-022-09437-z"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Boen HM, Cherubin M, Franssen C, et al. Circulating microRNA as biomarkers of anthracycline-induced cardiotoxicity:\u00a0JACC: CardioOncology\u00a0state-of-the-art review. JACC CardioOncol 2024;6:183\u201399. https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.009; PMID:\u00a038774014.","DOI":"10.1016\/j.jaccao.2023.12.009"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Dean M, Kim MJ, Dimauro S, et al. Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy \u2013 a prospective analysis. Cardiooncology 2023;9:23. https:\/\/doi.org\/10.1186\/s40959-023-00174-1; PMID:\u00a037106424.","DOI":"10.1186\/s40959-023-00174-1"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Van Boxtel W, Bulten BF, Mavinkurve-Groothuis AM, et al. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers 2015;20:143\u20138. https:\/\/doi.org\/10.3109\/1354750X.2015.1040839; PMID:\u00a025980453.","DOI":"10.3109\/1354750X.2015.1040839"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 2013;163:205\u201313. https:\/\/doi.org\/10.1111\/bjh.12516; PMID:\u00a023927520.","DOI":"10.1111\/bjh.12516"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer\u00a0therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2022;4:19\u201337. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101; PMID:\u00a035492815.","DOI":"10.1016\/j.jaccao.2022.01.101"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Mecinaj A, Gulati G, Heck SL, et al. Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. Cardiooncology 2021;7:33. https:\/\/doi.org\/10.1186\/s40959-021-00115-w; PMID:\u00a034579775.","DOI":"10.1186\/s40959-021-00115-w"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Hahn VS, Zhang KW, Sun L, et al. Heart failure with targeted cancer therapies: mechanisms and cardioprotection. Circ Res 2021;128:1576\u201393. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318223; PMID:\u00a033983833.","DOI":"10.1161\/CIRCRESAHA.121.318223"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144; PMID:\u00a017101852.","DOI":"10.1161\/CIRCULATIONAHA.106.635144"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016;37:1671\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022; PMID:\u00a026903532.","DOI":"10.1093\/eurheartj\/ehw022"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Heck SL, Mecinaj A, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 2021;143:2431\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054698; PMID:\u00a033993702.","DOI":"10.1161\/CIRCULATIONAHA.121.054698"},{"key":"ref46","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018;71:2281\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049; PMID:\u00a029540327."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Livi L, Barletta G, Martella F, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol 2021;7:1544\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3395; PMID:\u00a034436523.","DOI":"10.1001\/jamaoncol.2021.3395"},{"key":"ref48","unstructured":"Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 2018;94:126\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005; PMID:\u00a029567630."},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Meessen JMTA, Cardinale D, Ciceri F, et al. Circulating biomarkers and cardiac function over 3\u00a0years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail 2020;7:1452\u201366. https:\/\/doi.org\/10.1002\/ehf2.12695; PMID:\u00a032358917.","DOI":"10.1002\/ehf2.12695"},{"key":"ref50","unstructured":"Negishi T, Thavendiranathan P, Penicka M, et al. Cardioprotection using strain-guided management of potentially cardiotoxic\u00a0cancer therapy: 3-year results of the SUCCOUR trial. JACC Cardiovasc Imaging 2023;16:269\u201378. https:\/\/doi.org\/10.1016\/j.jcmg.2022.10.010; PMID:\u00a036435732."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830; PMID:\u00a027893331.","DOI":"10.1200\/JCO.2016.68.7830"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2016;2:1030\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1726; PMID:\u00a027348762.","DOI":"10.1001\/jamaoncol.2016.1726"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 2019;175:595\u2013603. https:\/\/doi.org\/10.1007\/s10549-019-05191-2; PMID:\u00a030852761.","DOI":"10.1007\/s10549-019-05191-2"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Leong DP, Cosman T, Alhussein MM, et al. Safety of continuing trastuzumab despite\u00a0mild\u00a0cardiotoxicity: a Phase I trial. JACC CardioOncol 2019;1:1\u201310. https:\/\/doi.org\/10.1016\/j.jaccao.2019.06.004; PMID:\u00a034396157.","DOI":"10.1016\/j.jaccao.2019.06.004"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Tajstra M, Dyrbu\u015b M, Rutkowski T, et al. Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. ESC Heart Fail 2023;10:3174\u201383. https:\/\/doi.org\/10.1002\/ehf2.14466; PMID:\u00a037449716.","DOI":"10.1002\/ehf2.14466"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bhalraam U, Veerni RB, Paddock S, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026; PMID:\u00a040044419; epub ahead of press.","DOI":"10.1093\/eurjpc\/zwaf026"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 2015;17:81\u20139. https:\/\/doi.org\/10.1002\/ejhf.196; PMID:\u00a025410653.","DOI":"10.1002\/ejhf.196"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Boulet J, Pe\u00f1a J, Hulten EA, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. J Am Heart Assoc 2019;8:e005996. https:\/\/doi.org\/10.1161\/JAHA.117.005996; PMID:\u00a031213106.","DOI":"10.1161\/jaha.117.005996"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Macedo AVS, Hajjar LA, Lyon AR, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol 2019;1:68\u201379. https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.003; PMID:\u00a034396164.","DOI":"10.1016\/j.jaccao.2019.08.003"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev 2022;9:CD014638. https:\/\/doi.org\/10.1002\/14651858.CD014638.pub2; PMID:\u00a036162822.","DOI":"10.1002\/14651858.CD014638.pub2"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. J Clin Oncol 2023;41:2248\u201357. https:\/\/doi.org\/10.1200\/JCO.22.02423; PMID:\u00a036669148.","DOI":"10.1200\/JCO.22.02423"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"de Baat EC, van Dalen EC, Mulder RL, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health 2022;6:885\u201394. https:\/\/doi.org\/10.1016\/S2352-4642(22)00239-5; PMID:\u00a036174614.","DOI":"10.1016\/S2352-4642(22)00239-5"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdh097; PMID:\u00a014998846.","DOI":"10.1093\/annonc\/mdh097"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Aloss K, Hamar P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics 2023;15:893. https:\/\/doi.org\/10.3390\/pharmaceutics15030893; PMID:\u00a036986754.","DOI":"10.3390\/pharmaceutics15030893"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Rafiyath SM, Rasul M, Lee B, et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012;1:10. https:\/\/doi.org\/10.1186\/2162-3619-1-10; PMID:\u00a023210520.","DOI":"10.1186\/2162-3619-1-10"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023; PMID:\u00a031959335.","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"ref67","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920; PMID:\u00a032463967."},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Mecinaj A, Gulati G, Ree AH, et al. Impact of the ESC cardio-oncology guidelines biomarker criteria on incidence of cancer therapy-related cardiac dysfunction. JACC CardioOncol 2024;6:83\u201395. https:\/\/doi.org\/10.1016\/j.jaccao.2023.10.008; PMID:\u00a038510299.","DOI":"10.1016\/j.jaccao.2023.10.008"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:04:26Z","timestamp":1758283466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2025.26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":69,"URL":"https:\/\/doi.org\/10.15420\/ecr.2025.26","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"article-number":"e23"}}